Experimental treatments for the Ebola virus have been introduced in eastern Democratic Republic of Congo, where the latest outbreak has severely affected the Ituri province. The new therapies are being administered at the Ebola treatment center within Bunia’s Evangelical Medical Centre, located in one of the regions most impacted by the outbreak.

The virus responsible for the current epidemic is the Bundibugyo strain, a less common variant of the Ebola virus for which no specific treatments or vaccines currently exist. To date, more than 1,400 cases have been confirmed, with 438 deaths recorded, according to World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus.

Last week, the WHO announced the enrollment of the first patient in a clinical trial designed to assess the effectiveness of two experimental treatments: the antiviral drug remdesivir and an antibody-based therapy known as MBP134. Researchers are evaluating whether these treatments, either individually or combined, can improve survival rates for those infected with Bundibugyo. Patient outcomes will be monitored over a 28-day period following treatment initiation, explained Dr. Vasee Moorthy, a WHO research adviser.

The trial is supported by the WHO and involves a partnership between the Democratic Republic of Congo’s national biomedical research institute, Oxford University, the Institute of Tropical Medicine in Antwerp, and various international health organizations. The current phase focuses on patients with confirmed Ebola infections receiving care within specialized treatment centers. Professor Yap Boum, head of emergency response at the Africa Centres for Disease Control and Prevention, indicated that a subsequent phase will extend the study to include healthcare workers, close contacts, and others deemed at high risk of infection.

Local residents have expressed cautious optimism about the new treatment efforts. Audrey Tengetenge, a Bunia resident, described the trials as a "light at the end of the tunnel" and expressed hope for swift progress to bring relief to communities devastated by the outbreak. "We want nothing more than an end to this very dangerous disease, which continues to bring us grief," she said.

The Bundibugyo strain’s rarity and the lack of targeted vaccines have posed significant challenges to controlling the outbreak. The introduction of these experimental treatments marks a critical step in efforts to reduce mortality and contain the virus as the crisis continues to unfold.